Introduction
Endometrial cancer (EC) is one of the most common malignant neoplasms of the female reproductive tract (1) . The prevalence of EC has increased in recent years, especially in developed countries. If EC is treated in the early stage (I and II FIGO stage), the chance of 5-year survival is relatively high. However, when recurrent or advanced EC (III and IV FIGO stage) is diagnosed, survival rate decreases to about 15-50% (2) . According to the classical dualistic Bokhman's model, EC can be divided into two clinicopathological subclasses: type I EC (estrogen-dependent, 70-80% cases) and type II EC (estrogen-nondependent, 20-30% cases). Type I consists of endometrioid endometrial carcinomas (EEC), which are usually lowstage and low-grade tumors with favorable prognosis. Type II consists of poorly differentiated serous/clear cell carcinomas, which are clinically aggressive and tend to form metastases or recurrences (3) . The Cancer Genome Atlas (TCGA) study, based on genomic, transcriptomic and proteomic characterization of 373 ECs, proved that Bokhman's model is oversimplified (4) . Although histologically different, some EECs may behave clinically as type II carcinomas and share the same molecular or pathological characteristics. Therefore, it seems to be important to identify such clinically unpredictable carcinomas, which might be resistant to treatment. Use of such markers would allow us to modify and individualize the treatment in cases of clinically aggressive tumors. MicroRNAs (miRNAs) are robust and stable molecules that seem to be ideal for molecular studies dedicated to the identification of markers.
MicroRNAs are small, non-coding RNA molecules of 18-25 nucleotides (5). They function as cellular regulators, taking part in RNA silencing and post-transcriptional regulation of gene expression. The miRNA binds to the 3 0 -untranslated region of target mRNAs, causing translational repression, mRNA cleavage or decay (6) . Such critical processes as apoptosis, proliferation and cell differentiation may be partially dependent on miRNA activity (7) . Aberrant expression of miRNAs has been reported in multiple neoplasms, including EC. Numerous evidence suggests that miRNAs may play an important role in carcinogenesis and tumor growth. Although several authors have reported aberrant expression of many miRNAs in EC, there is still no consensus on which dysregulated miRNAs are characteristic for endometrial tumors. Among other miRNAs, the miRNA-200 family is believed to be differentially expressed in EC (8) . The miRNA-200 family consists of five miRNAs: miR-200a, miR-200b, miR-200c, miR-141 and miR-429 (9). These miRNAs negatively regulate expression of ZEB1 and ZEB2 (transcriptional repressors of the E-cadherin), which are critical factors for epithelial to mesenchymal transition (EMT) (10) .
Expression of miRNAs has been extensively studied in diverse malignancies; however, the data concerning their prognostic role, especially in female tumors, is scarce. Several authors have reported that expression of miR-200c in EC tissues is different in comparison to normal endometrium. Despite the fact that miRNA200c seems to be one of the key-regulators of EC carcinogenesis, its prognostic and clinical significance has not been fully evaluated, yet. Only two studies have described the diagnostic role of miRNA-200c in women with EC and its impact on survival (11, 12) . Therefore, we decided to investigate miRNA-200c expression levels in EEC tissues and evaluate them with regard to clinicopathological characteristics, with special concern for patient survival.
Material and methods
Ninety women who received surgery for EEC between 2002 and 2014 were selected. Total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy was performed in all cases. Adjuvant treatment was employed in the majority of patients. In the case of stage IA G1 tumors, additional postoperative therapy was not necessary. General information on pathological features, adjuvant treatment applied, age, survival, recurrence and follow-up data were obtained from medical records. We retrieved data on the recurrence and survival rates in all patients. Additionally, a survey among patients was carried out. Basic clinical and pathological data are presented in Tables 1 and 2 . Expression levels of miRNA200c were evaluated in formalin-fixed, paraffin-embedded (FFPE) EEC tissues. An experienced pathologist carried out a precise re-evaluation of the specimens and selected areas with representative EEC samples. Then, a careful microdissection was performed (Laser Microdissection -MMI CellCut). Ten samples of normal endometrium were retrieved after hysterectomy for benign diseases and were used to create a reference group. Endometrial control samples were collected from perimenopausal (six samples) and postmenopausal (four samples) women. The number of samples in the reference group was dependent on the reproducibility and consistency of miRNA-200c expression levels.
RNA isolation was performed with the use of an miRNeasy FFPE Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. Samples were consecutively Relative expression levels of the studied miRNA200c, expressed as relative quantity (RQ) values, were determined using DDCT method, adjusted to the expression of RNU6B (endogenous control) and related to the expression level of calibrator (RQ= 1). Kaplan-Meier survival analysis was used to assess the relation between miRNA-200c expression and patient survival rate. The log-rank test was used to compare survival curves. The cut-off value for miRNA-200c was determined using X-tile plots based on the association with mortality of the patients. X-tile plots provide a simple method to assess the association between variables and survival. The X-tile program selects the optimum data cut point according to the highest chi-squared value (minimum p-value) defined by Kaplan-Meier survival analysis and log-rank test (14) . We performed the X-tile plots using the X-TILE software version 3.6.1 (Yale University School of Medicine, New Haven, CT).
Ethical approval
All women provided their written consent and the Polish Mother's Memorial Hospital Research Institute Ethics Committee granted an approval for the study (no. 12/ 2014, issued on 27 May 2014).
Results
Normal endometrium samples were characterized by reproducibly low miRNA-200c expression levels. Statistical estimation indicated that there was no need to exceed the number of samples in the control group. The miRNA-200c was significantly upregulated in the EEC tissues in comparison to normal endometrium (mean RQ for cancer 2.098, mean RQ for control tissues 0.971, p = 0.005; Figure 1 ). We evaluated miRNA-200c expression levels with regard to such clinicopathological data as: survival, distant metastases, recurrence rate, grading, FIGO stages, positive lymph nodes and myometrial infiltration. Statistical analysis revealed that there was no correlation between grading and miRNA-200c expression (p = 0.75). Similarly, no association was found between miRNA-200c expression and the depth of myometrial invasion. We found no differences in miRNA-200c levels between women affected by <½ myometrial invasion and Figure 2 ). We did not find a correlation between body mass index and miRNA-200c expression levels (p = 0.21). Additionally, we performed univariate and multivariate analyses in regard to standard clinical and pathological prognostic factors that may provide information on the patients' outcome. All prognostic factors were correlated to the overall and disease-free survival (Table 3 ). In the studied group, 20 women died. In two cases death occurred due to related comorbidities (22 and 33 months after the initial treatment, both early-stage EEC patients). There were 18 cases of recurrent disease. We observed four women who were successfully treated after being diagnosed with a local relapse. In 14 cases recurrent disease was fatal. The majority of women who died due to EEC did so within 2 years after the surgery (17 deaths, median time of death 12 months AE SD 6.9 months). Only one woman died due to recurrent EEC 65 months after the primary therapy (51 months of disease-free survival, FIGO stage II). Altogether, only five deaths due to EEC were observed in women with early-stage disease (FIGO stage I/II). Death occurred in 13 women who were diagnosed with advanced cancer (FIGO stage III/IV). Among those women, four deaths were related to the progression of the initially advanced, persistent disease and nine were related to the presence of recurrence. Analysis of miRNA-200c expression did not demonstrate any relation to disease-free nor overall survival (Table 3) . Table 3 presents univariate and reduced models of multivariable analysis. The full model of multivariable analysis was performed with all variables with p < 0.2 to avoid type II error, and the results remained unchanged (data not shown). Figure 3 ). Lower levels of miRNA-200c, in contrast, were observed in women who tended to have shorter survival. Similarly, we also used Kaplan-Meier analysis to evaluate disease-free survival. Higher levels of miRNA-200c were detected in women who were characterized by more favorable disease-free survival (log rank test; p = 0.028, hazard ratio 0.61, 95% CI 0.48-0.81, Figure 4 ).
Discussion
Dysregulation of miRNA-200 family members has been reported by several authors. Snowdon et al. conducted an miRNA profiling study in both normal and pathological endometrium samples and reported that the entire miRNA-200 is upregulated in EEC tissues (15) . Likewise, Lee et al. evaluated differential expression of miRNAs in EEC. The authors proved that EEC is characterized by higher levels of miRNA-200c expression in comparison to (18) performed a study in which they attempted to evaluate the association between the use of hormone replacement therapy and circulating exomiR content. They reported that circulating exomiR clusters could be used as indicators of metabolic and inflammatory status affected by hormonal changes at menopause. Such data suggest that miRNAs in endometrial tissues may be modified to some extent by changes in estrogen levels in serum. However, there are no studies reporting such impact in the case of miRNA-200 family.
In our study, we confirmed that miRNA-200c levels are elevated in EEC tissues, which is consistent with findings by other authors. Upregulation of the miRNA200c suggests that it may play an important role in processes related to cancer promotion, tumor growth/ invasion, cell migration or metastasis. Therefore, we attempted to determine relations between miRNA-200c expression and clinicopathological findings in women with EEC. Contrary to many other authors, we decided to perform quantitative RT-PCR on biological material derived solely from women with EEC. Inclusion of heterogeneous histological tumor subtypes in the study might have led to misinterpretation of the results, as type I and II ECs are characterized by different molecular landscapes (19) . Nevertheless, we did identify significantly higher levels of miRNA-200c in the early stages of EEC. Such discrepancies mentioned above may be caused by a small number of women with high-grade and advanced stages of EEC included in our study. Furthermore, the results may also be dependent on the normalization strategy that we implemented. RNU6B, that was used in our study, is abundant in human tissues and is frequently recommended as a human endogenous control (21) . Despite the facts mentioned above, some authors claim that there are more stable and suitable controls for quantitative RT-PCR in human tissues, such as RNU44/RNU48 (22) .
Our results indicate that there is a difference in miRNA-200c expression levels between early-stage and late-stage EEC. Statistical analysis revealed that miRNA200c expression remained at significantly higher levels in the early stage EEC (FIGO stages I and II). Lower miRNA-200c levels were detected in more advanced EEC. Therefore, it is not surprising that lower miRNA-200c expression levels were associated with less favorable prognosis (according to Kaplan-Meier analysis). It shows that miRNA-200c expression levels might be a potential prognostic factor, which can distinguish between more and less advanced stages of EEC. Assessment of miRNA-200c levels might be clinically relevant and could allow the identification of high-risk patients. Pelvic lymph node metastases occur in approximately 10% of patients with disease confined to the uterine corpus. However, some authors claim that there is no benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early EC (23) . Such risk factors as tumor type, stage, grade or depth of myometrial invasion are used to identify women who need adjuvant treatment. Evaluation of miRNA-200c preoperatively, especially in cases of disease confined to the uterus, might be useful in the selection of high-risk patients. High-risk patients could receive more aggressive treatment by performing systemic lymphadenectomy or introducing adjuvant treatment. Such a hypothesis, however, needs further clinical verification.
miRNA-200c may be one of the key players in cancer initiation and progression, but it may act in a different manner in various human malignancies. Its expression levels may be dependent on the histological type or localization of the tumor. In the case of EEC, miRNA-200c expression, even globally upregulated, may vary in earlyand late-stage tumors. Unfortunately, molecular mechanisms of action of miRNA-200c in EC has not been fully elucidated, therefore, it is difficult to prove such an assumption. One of the possible ways in which miRNA200c impacts cancer progression is the EMT. This is a vital process in which epithelial cells lose their polarity and adhesive capabilities. Cells that undergo the EMT process gain migratory and invasive properties. E-cadherin transcriptional repressors ZEB1/ZEB2 (zinc-finger E-box-binding homeobox 1 and 2) are regulated by miRNA-200 family members (10) . Korpal et al. found that overexpression of miRNA-200 may hinder the EMT process by enhancing E-cadherin expression through direct targeting of ZEB1 and ZEB2 (24) . EMT might be a process that is characteristic for more advanced and progressed tumors. In view of the above, lower levels of miRNA-200c may be indicative for late-stage ECs, which hold high metastatic potential. Despite miRNA-200c being upregulated in both early-and late-stage ECs, it may be hypothesized that its overexpression would fall along with tumor progression and possible EMT induction. Lower levels of miRNA-200c in advanced EC may be caused by hypermethylation of the promoter region of the miR-200c/-141 cluster (25, 26) . Recently, a new molecular mechanism concerning EMT has been discovered. Li et al. found that miR-200c binds directly to MALAT1 (long noncoding RNA metastasis associated lung adenocarcinoma transcript 1). Transforming growth factor-b, which is a commonly known EMT inducer, increases MALAT1 expression by inhibiting miR-200c (27) . Another potential impact of miRNA-200c on EC is the inhibition of angiogenesis. miRNA-200c has been shown to directly target KDR (VEGF receptor 2) (28). Such molecular mechanisms described above emphasize the role of miRNA-200c as a suppressor of tumor progression and metastasis. Nevertheless, it seems that miRNA-200c may also act as a tumor oncogene. In vitro molecular evidence suggest that these miRNAs play an oncogenic role. Park et al. found that miRNA-200c inhibits a potential suppressor gene -BRD7 (bromodomain containing 7). According to the authors, inhibition of BRD7 leads to translocation of b-catenin from the cytoplasm to the nucleus, which results in activation of cyclin D1 and c-myc (29) . Despite all the recent findings, the molecular mechanisms of miRNA-200c action in EC still remain controversial.
Prognostic significance of miRNA-200c has been analyzed by several authors, but only two studies were performed on EC tissues. Karaayvaz et al. showed that expression levels of miR-200c were not associated with patient survival (11) . Their study was based on only 48 EC cases of mixed histology. Torres et al. performed a Kaplan-Meier survival analysis, which revealed that an miRNA signature of miR-1228/miR-200c/miR-429 proved to be an independent prognostic marker of overall survival (12) . Our results suggest that higher levels of miRNA-200c are associated with improved survival among women with EEC. This finding is concordant to the fact that miRNA200c may act as a tumor suppressor, therefore, its relatively high levels could play a protective role. Apart from EC, the prognostic significance of miRNA-200c has also been studied in other malignancies. Wu et al. performed a metaanalysis based on 23 studies that included various carcinomas and concluded that there was no significant association between miRNA-200c levels and overall survival (30). Shao et al. included 18 studies in their analysis, indicating that miRNA-200c expression in tissue showed no correlation with overall survival nor progression-free survival. However, they concluded that downregulation of tissue miR-200c predicted poor overall survival of women with stage I disease (31) .
We aimed primarily to verify clinical usefulness of miRNA-200c expression levels in women with EEC. Therefore, we abandoned experiments that would lead to clarification of the molecular role of miRNA-200c in EEC and instead focused only on its clinical significance. Despite the fact that miRNA-200c seems to play an important role in tumor growth and carcinogenesis, its exact molecular mechanisms of action in EEC have not been established. Identification of the molecular role of miRNA-200c and its related genes would be a beneficial addition to our study. According to several authors, miRNA-200c expression levels may be associated with previously mentioned ZEB1/ZEB2, KDR or BRD7. Further identification of their role with regard to miRNA-200c and the prognosis of women with EEC should be investigated in the future. Moreover, miRNA expression and regulation in endometrium may be influenced by such factors as hormone intake or other environmental components -a role that still needs to be determined before introducing miRNAs into clinical practice.
In summary, our results indicate that higher miRNA200c tissue levels could be associated with more favorable prognosis and less advanced stages of EEC. Our study was not specifically designed to assess the miRNA-200c expression levels as a prognostic factor. We aimed to find an association between miRNA-200c expression levels and multiple clinicopathological factors, with special concern for patient survival. Lower miRNA-200c expression levels were detected in advanced stages of EEC and, therefore, were associated with less favorable prognosis. It seems that survival analysis of only women with FIGO stage I and II disease would be more relevant in assessment of the true miRNA-200c prognostic significance. Our study included too few women with early-stage disease to conduct such an assessment, especially taking into consideration the fact that EEC is characterized by relatively good prognosis when the disease is confined only to the uterine corpus. Possible clinical utility of miRNA-200c as a prognostic factor should be evaluated on larger groups of women with EEC. 
